CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)

NCT02675946 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors
GI Cancer

Interventions

DRUG: CGX1321
DRUG: Pembrolizumab
DRUG: encorafenib
DRUG: cetuximab

Sponsor

Curegenix Inc.

Collaborators

[object Object]